A comprehension of signaling pathways and drug resistance; an insight into the correlation between microRNAs and cancer.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 03 08 2023
revised: 02 10 2023
accepted: 02 10 2023
medline: 13 11 2023
pubmed: 21 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

Despite the development of numerous therapies, cancer remains an incurable disease due to various factors, including drug resistance produced by cancer cells. MicroRNAs (miRNAs) regulate different target genes involved in biological and pathological processes, including cancer, through post-transcriptional mechanisms. The development of drug resistance in cancer treatment is a significant barrier because it decreases drug uptake, cellular transport, and changes in proteins involved in cell proliferation, survival, and apoptotic pathways. Numerous studies have found a connection between miRNAs and the development of drug resistance in cancer cells. This paper provides a broad overview of how miRNAs regulate signaling pathways and influence treatment resistance in different cancers.

Identifiants

pubmed: 37862919
pii: S0344-0338(23)00549-6
doi: 10.1016/j.prp.2023.154848
pii:
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

154848

Informations de copyright

Copyright © 2023 Elsevier GmbH. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hashem O Alsaab (HO)

Department of Pharmaceutics and Pharmaceutical Technology, Taif University, Taif 21944, Saudi Arabia. Electronic address: hashemalsaab@gmail.com.

Bekhzod Abdullaev (B)

Research Department of Biotechnology, New Uzbekistan University, Mustaqillik Avenue 54, Tashkent 100007, Uzbekistan; Department of Oncology, School of Medicine, Central Asian University, Milliy Bog Street 264, Tashkent 111221, Uzbekistan. Electronic address: author.uzb@mail.ru.

Adnan Taan Alkhafaji (AT)

Cardiology Department, College of Medicine, Al-Ayen University, Dhi-Qar, Iraq.

Ahmed Hussien Alawadi (AH)

College of Technical Engineering, the Islamic University, Najaf, Iraq; College of Technical Engineering, the Islamic University of Al Diwaniyah, Iraq; College of Technical Engineering, the Islamic University of Babylon, Iraq.

Ibtesam Jahlan (I)

Maternal and Child Health Nursing Department, King Saud University, Riyadh, Saudi Arabia.

Hala Bahir (H)

Medical Technical College, Al-Farahidi University, Baghdad, Iraq.

Yashwant Singh Bisht (YS)

Department of Mechanical Engineering, Uttaranchal Institute of Technology, Uttaranchal University, Dehradun 248007, India.

Ali Alsaalamy (A)

College of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna 66002, Iraq.

Abeer Mhussan Jabbar (AM)

College of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq.

Yasser Fakri Mustafa (YF)

Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul 41001, Iraq.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH